Pharmaceuticals and Healthcare Report Q3 2012 for Multiple Europe Countries on
MarketReportsOnline.com adds Q3 2012 reports for Pharmaceuticals and Healthcare industry of
multiple Europe countries to its store. Following are the report briefs:
Germany Pharmaceuticals and Healthcare Report Q3 2012
While the increased consumption of generic medicines will have an impact on the overall
pharmaceutical market forecast for Germany, we note that government measures such as the three-
year freeze on price rises for prescription drugs, as well as the implementation of mandatory discounts
of up to 16% on patented drugs, will weigh more heavily on overall pharmaceutical market growth.
Poland Pharmaceuticals and Healthcare Report Q3 2012
Despite numerous challenges, we continue to believe Poland is the most attractive pharmaceutical
market in Central and Eastern Europe (CEE). While the long-awaited Drug Reimbursement Act
introduced in Q112 faced fierce opposition from the public and members of the healthcare profession,
and also resulted in volatility of pharmaceutical spending, we maintain our view of positive growth for
2012, projecting 1.6% year-on-year (y-o-y) expansion.
Portugal Pharmaceuticals and Healthcare Report Q3 2012
A year has passed since the EU/IMF/ECB’s rescue package was approved, and the obligations that form
part of the economic adjustment programmed have had, and will continue to have, a central role in
redefining Portugal’s pharmaceutical and healthcare market. Cost-cutting measures are continuous:
generic drug prices dropped (again) in May 2012, this time by an average of 20%; new legislation
enacted in March 2012 means that patented medicines will be subjected to automatic price
cuts once their patent expires; and physicians are now obliged to prescribe by active ingredient. The
implications of these cuts are widespread. Delays in payments are threatening the economic viability of
many pharmacies and wholesalers’ operations, while Roche decided to suspend the supply of drugs to
23 public hospitals in February 2012 because of payment arrears. On the upside, Health Cluster Portugal
reports that pharmaceutical exports now exceed those of wine or cork and that the sector has potential
for further growth, while Portugal’s long-awaited intellectual property court began operations in March
2012, offering the manufacturers of patented drugs additional operational security.
Bulgaria Pharmaceuticals and Healthcare Report Q3 2012
While the recently appointed new heads at the Bulgarian Ministry of Health and the National Health
Insurance Fund (NHIF) are now clearly looking at more aggressive mechanisms for cutting drug prices in
the country, despite the short-term challenges we still believe the market is attractive and will generate
high single-digit yearly growth over our five-year forecast period. Our 2012- 2013 industry forecast
scenario for Bulgaria’s pharmaceutical market is governed by two main factors. Namely, short-term
negotiations of medicine price cuts and the likelihood that the health ministry and the NHIF will push
ahead with more far-reaching legislative changes to how Bulgaria prices its medicines.
Slovenia Pharmaceuticals and Healthcare Report Q3 2012
Our view that Slovenia’s drug market is one of the most stable in the region remains in place despite the
fact that - at the start of 2012 - the government published new measures to control public drug
expenditure. The government’s methods are considerably less aggressive than those in other Central
and Eastern European (CEE) markets, and are as such not expected to result in the market value decline.
Jordan Pharmaceuticals and Healthcare Report Q3 2012
The development of Jordan’s medical facilities and infrastructure, partly driven by the country’s aim to
increase its attractiveness for medical tourists from across the globe, will provide solid longer-term
commercial opportunities for companies involved in the field. However, makers of innovative medicines
will continue to face market access barriers in the shape of unfavorable pricing and intellectual property
(IP) regimes, while the authorities’ attempt to increase access to medicines is set to result in
encouraging the use of cheaper generic medicines. Still, while we expect a decline in the patented drug
market’s share of the total by value, the absolute value of the segment will increase.
Oman Pharmaceuticals and Healthcare Report Q3 2012
While a higher healthcare budget in 2012 and the expansion of healthcare facilities will be conducive to
pharmaceutical companies operating in Oman, the country’s small population and strict price controls
will continue to place downward pressure on overall values. Nevertheless, the population increasing and
ageing will remain an attraction, especially as patented medicines continue to represent the bulk of
pharmaceutical spending in the country.
Browse more Reports on Pharmaceuticals @ www.marketreportsonline.com/cat/pharmaceuticals-
More Reports by Business Monitor International @
Contact email@example.com to order OR for further information.